If you know anything about facial balancing, you know the chin is a pivotal area. And now there is a new FDA-approved option to treat it. Galderma’s Restylane Lyft has been officially cleared to enhance the chin in adults with mild to moderate retrusion, giving injectors another nonsurgical tool to add structure to the lower face.
In clinical trials, patients saw meaningful improvement by three months, and those results stayed strong through a full year. Patients and investigators also reported high satisfaction with natural-looking definition and a smoother transition from chin to jawline.
Already cleared for the midface, smile lines and hands, Restylane Lyft is known for its firmer gel and support-forward lift. With this new indication, the filler steps into a key role for lower-face refinement, where subtle projection can strengthen the profile and support jawline contour.
“This approval reinforces our commitment to advancing our Injectable Aesthetics portfolio—the broadest on the market—to meet the diverse needs of patients. By expanding how innovations like Restylane Lyft can be used, we aim to empower aesthetic practitioners to achieve their patients’ unique aesthetic goals with enhanced flexibility and precision,” said Bill Andriopoulos, Vice President of Medical Affairs at Galderma, in a press release.
This new approval gives injectors another way to shape and define the chin without surgery or downtime. With more people paying attention to lower-face contouring, interest in treatments that create a balanced, natural-looking profile isn’t slowing down anytime soon.
